Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

IL1 blockade in crystal-induced arthritis: impact of disease duration and the inflammatory syndrome. Comments on the article by Couderc M. et al. "Efficacy of anakinra in articular chondrocalcinosis".

Verhoeven F, Prati C, Godfrin-Valnet M, Guillot X, Wendling D.

Joint Bone Spine. 2013 Jan;80(1):115-6. doi: 10.1016/j.jbspin.2012.09.002. Epub 2012 Oct 24. No abstract available.

PMID:
23103080
2.

Reply to the comment by Verhoeven et al. about the article "Efficacy of anakinra in articular chondrocalcinosis--report of three cases" Joint Bone Spine 2012;79:330-1.

Couderc M, Soubrier M.

Joint Bone Spine. 2013 Jan;80(1):116. doi: 10.1016/j.jbspin.2012.10.003. Epub 2012 Nov 16. No abstract available.

PMID:
23165180
3.

Efficacy of anakinra in articular chondrocalcinosis: report of three cases.

Couderc M, Mathieu S, Glace B, Soubrier M.

Joint Bone Spine. 2012 May;79(3):330-1. doi: 10.1016/j.jbspin.2011.12.017. Epub 2012 Feb 15. No abstract available.

PMID:
22341584
4.

Interleukin 1β blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment.

Diamantopoulos AP, Brodin C, Hetland H, Haugeberg G.

J Clin Rheumatol. 2012 Sep;18(6):310-1. doi: 10.1097/RHU.0b013e31826149a2.

PMID:
22832289
5.

Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure.

Announ N, Palmer G, Guerne PA, Gabay C.

Joint Bone Spine. 2009 Jul;76(4):424-6. doi: 10.1016/j.jbspin.2009.01.001. Epub 2009 Mar 16.

PMID:
19289295
6.

Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature.

Ottaviani S, Brunier L, Sibilia J, Maurier F, Ardizzone M, Wendling D, Gill G, Palazzo E, Meyer O, Dieudé P.

Joint Bone Spine. 2013 Mar;80(2):178-82. doi: 10.1016/j.jbspin.2012.07.018. Epub 2012 Sep 28. Review.

PMID:
23022422
7.

Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis.

Moltó A, Ea HK, Richette P, Bardin T, Lioté F.

Joint Bone Spine. 2012 Dec;79(6):621-3. doi: 10.1016/j.jbspin.2012.01.010. Epub 2012 Jun 1.

PMID:
22658375
8.

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.

Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, Pinto G, Pagnier A, Bodemer C, Bodaghi B, Tardieu M, Prieur AM, Quartier P.

Arthritis Rheum. 2010 Jan;62(1):258-67. doi: 10.1002/art.25057.

9.

IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease.

Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F, Burmester GR.

Ann Rheum Dis. 2010 Feb;69(2):466-7. doi: 10.1136/ard.2009.108068. No abstract available.

PMID:
20107032
10.

Successful treatment of resistant pseudogout with anakinra.

McGonagle D, Tan AL, Madden J, Emery P, McDermott MF.

Arthritis Rheum. 2008 Feb;58(2):631-3. doi: 10.1002/art.23119.

11.

Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.

Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, Kunkel G, Schlesinger M, Bohnsack J.

J Clin Rheumatol. 2009 Jun;15(4):161-4. doi: 10.1097/RHU.0b013e3181a4f459.

PMID:
19363453
12.

Efficacy of interleukin 1 receptor antagonist (anakinra) on a refractory case of Schnitzler's syndrome.

Kluger N, Rivière S, Guillot B, Bessis D.

Acta Derm Venereol. 2008;88(3):287-8. doi: 10.2340/00015555-0404. No abstract available.

13.

Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature.

Aouba A, Deshayes S, Frenzel L, Decottignies A, Pressiat C, Bienvenu B, Boue F, Damaj G, Hermine O, Georgin-Lavialle S.

Mediators Inflamm. 2015;2015:792173. doi: 10.1155/2015/792173. Epub 2015 Mar 26. Review.

14.

Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases.

Botsios C, Sfriso P, Ostuni PA, Todesco S, Punzi L.

Rheumatology (Oxford). 2007 Jun;46(6):1042-3. Epub 2007 Apr 19. No abstract available.

PMID:
17449489
15.

The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study.

Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC.

J Neurol Sci. 2013 Nov 15;334(1-2):123-5. doi: 10.1016/j.jns.2013.08.007. Epub 2013 Aug 14.

PMID:
23998706
16.

Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra.

Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P.

Br J Dermatol. 2009 Nov;161(5):1199-201. doi: 10.1111/j.1365-2133.2009.09404.x. Epub 2009 Aug 10.

PMID:
19673875
17.

Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case report.

Furlan A, Botsios C, Ruffatti A, Todesco S, Punzi L.

Joint Bone Spine. 2008 May;75(3):366-7. Epub 2007 Oct 22. No abstract available.

PMID:
18068393
18.

Clinical benefits of intra-articular anakinra for persistent knee effusion.

Brown C, Toth A, Magnussen R.

J Knee Surg. 2011 Mar;24(1):61-5.

PMID:
21618940
19.

Is the serum amyloid A we use really serum amyloid A? Comment on the article by Connolly et al.

van den Brand B, Waterborg C, van den Berg W, van de Loo F.

Arthritis Rheum. 2013 Jan;65(1):283-4. doi: 10.1002/art.37737. No abstract available.

20.

Is the serum amyloid A we use really serum amyloid A? Comment on the article by Connolly et al. Reply.

Mullan RH, Connolly M, Veale DJ, Fearon U.

Arthritis Rheum. 2013 Jan;65(1):284-5. doi: 10.1002/art.37736. No abstract available.

Supplemental Content

Support Center